Vibliome Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$22M
- Investors
-
2
Vibliome General Information
Description
Developer of small-molecule Type II kinase inhibitors designed to treat inflammatory diseases and castration-resistant prostate cancer. The company is focused on analyzing the design of Type II inhibitors that lock kinase targets in an inactive conformation, helping in identifying unique similarities and differences between kinases, enabling clinical researchers to develop drugs for cancer as well as other chronic diseases.
Contact Information
Website
www.vibliome.comCorporate Office
- 533 East Mendenhall Street
- Bozeman, MT 59715
- United States
Corporate Office
- 533 East Mendenhall Street
- Bozeman, MT 59715
- United States
Vibliome Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 24-Feb-2022 | $22M | Completed | Pre-Clinical Trials | ||
| 3. Early Stage VC (Series A) | 15-Feb-2019 | Completed | Product Development | |||
| 2. Angel (individual) | 12-Apr-2018 | $113K | $113K | Completed | Startup | |
| 1. Grant | 02-Nov-2017 | $500K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Vibliome Comparisons
Industry
Financing
Details
Vibliome Competitors (2)
One of Vibliome’s 2 competitors is Plexium, a Venture Capital-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Plexium | Venture Capital-Backed | San Diego, CA | ||||
| AVEO Oncology | Formerly VC-backed | Boston, MA |
Vibliome Patents
Vibliome Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026228825-A1 | Crystalline forms of plk4 modulating compounds | Pending | 30-Apr-2025 | ||
| AU-2024369826-A1 | Plk4 modulators | Pending | 30-Oct-2023 | ||
| EP-4801907-A1 | Plk4 modulators | Pending | 30-Oct-2023 | ||
| WO-2025096463-A1 | Plk4 modulators | Inactive | 30-Oct-2023 | ||
| WO-2023183444-A1 | Modulators of protein kinases | Inactive | 24-Mar-2022 | C07D473/00 |
Vibliome Signals
Vibliome Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Deerfield Management | Venture Capital | Minority | ||
| Male Contraception Initiative (MCI) | Corporation |
Vibliome FAQs
-
When was Vibliome founded?
Vibliome was founded in 2017.
-
Where is Vibliome headquartered?
Vibliome is headquartered in Bozeman, MT.
-
What is the size of Vibliome?
Vibliome has 11 total employees.
-
What industry is Vibliome in?
Vibliome’s primary industry is Drug Discovery.
-
Is Vibliome a private or public company?
Vibliome is a Private company.
-
What is Vibliome’s current revenue?
The current revenue for Vibliome is .
-
How much funding has Vibliome raised over time?
Vibliome has raised $38.1M.
-
Who are Vibliome’s investors?
Deerfield Management and Male Contraception Initiative (MCI) have invested in Vibliome.
-
Who are Vibliome’s competitors?
Plexium and AVEO Oncology are competitors of Vibliome.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process